A detailed history of Congress Park Capital LLC transactions in Amgen Inc stock. As of the latest transaction made, Congress Park Capital LLC holds 6,595 shares of AMGN stock, worth $2.04 Million. This represents 0.83% of its overall portfolio holdings.

Number of Shares
6,595
Previous 7,055 6.52%
Holding current value
$2.04 Million
Previous $2.03 Million 7.68%
% of portfolio
0.83%
Previous 0.99%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$268.87 - $324.56 $123,680 - $149,297
-460 Reduced 6.52%
6,595 $1.88 Million
Q4 2022

Jan 27, 2023

SELL
$229.03 - $291.01 $5,725 - $7,275
-25 Reduced 0.35%
7,055 $1.85 Million
Q3 2022

Oct 18, 2022

SELL
$224.46 - $253.15 $11,223 - $12,657
-50 Reduced 0.7%
7,080 $1.6 Million
Q2 2022

Jul 22, 2022

SELL
$230.71 - $256.74 $115,355 - $128,370
-500 Reduced 6.55%
7,130 $1.74 Million
Q1 2022

May 02, 2022

SELL
$219.27 - $242.57 $76,744 - $84,899
-350 Reduced 4.39%
7,630 $1.85 Million
Q4 2021

Feb 09, 2022

BUY
$198.88 - $227.6 $119,328 - $136,560
600 Added 8.13%
7,980 $1.8 Million
Q3 2021

Nov 03, 2021

BUY
$212.27 - $248.7 $63,681 - $74,610
300 Added 4.24%
7,380 $1.57 Million
Q2 2021

Aug 13, 2021

SELL
$233.58 - $259.14 $10,511 - $11,661
-45 Reduced 0.63%
7,080 $1.73 Million
Q4 2020

Jan 19, 2021

SELL
$216.38 - $257.67 $5,409 - $6,441
-25 Reduced 0.35%
7,125 $1.64 Million
Q2 2020

Jul 27, 2020

SELL
$197.81 - $242.74 $9,890 - $12,137
-50 Reduced 0.69%
7,150 $1.69 Million
Q4 2018

Feb 06, 2019

SELL
$178.4 - $208.25 $7,136 - $8,330
-40 Reduced 0.55%
7,200 $1.4 Million
Q1 2018

Apr 17, 2018

SELL
$169.43 - $198.0 $76,243 - $89,100
-450 Reduced 5.85%
7,240 $1.23 Million
Q4 2017

Feb 13, 2018

BUY
$168.79 - $188.59 $1.3 Million - $1.45 Million
7,690
7,690 $1.34 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $165B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Congress Park Capital LLC Portfolio

Follow Congress Park Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Park Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Congress Park Capital LLC with notifications on news.